Table 5. Multivariate Cox analyses of CSS in ER+/PR−/HER-2− patients and ER−/PR+/HER-2− patients.

	ER+/PR−				ER−/PR+
	OR	95% CI	P value		OR	95% CI	P value
Age at diagnosis (vs. ≤40)
41–55	1.28	1.06–1.55	0.011		1.13	0.74–1.70	0.575
55–70	1.21	1.01–1.46	0.043		1.21	0.79–1.86	0.380
71–85	1.91	1.56–2.34	<0.001		2.16	1.35–3.46	0.001
>85	3.39	2.65–4.33	<0.001		2.16	1.02–4.57	0.045
Race recode (vs. White)
Black	1.26	1.13–1.40	<0.001		0.95	0.72–1.27	0.747
Marital status (vs. married)
Unmarried	1.17	1.07–1.29	0.001		1.09	0.84–1.42	0.509
Insurance recode (vs. insured)
Any medicare	1.19	1.06–1.33	0.003		1.21	0.90–1.64	0.209
Uninsured	1.34	1.06–1.70	0.013		2.11	1.04–4.25	0.038
Histology (vs. IDC)
LC	0.88	0.77–1.02	0.082		1.34	0.53–3.35	0.534
IDC + LC	0.85	0.68–1.05	0.135		1.44	0.69–3.00	0.333
Grade (vs. I-II)
III-IV	1.92	1.74–2.12	<0.001		2.36	1.52–3.66	<0.001
AJCC T stage (vs. ≤T1)
T2	2.12	1.86–2.42	<0.001		1.36	0.97–1.90	0.075
T3	2.89	2.46–3.40	<0.001		2.44	1.57–3.78	<0.001
T4	3.48	2.96–4.10	<0.001		3.24	2.13–4.92	<0.001
Surgery (vs. no surgery)
Conserving	0.35	0.29–0.42	<0.001		0.25	0.16–0.39	<0.001
Mastectomy	0.47	0.39–0.56	<0.001		0.31	0.19–0.50	<0.001
Radical	0.54	0.45–0.64	<0.001		0.45	0.28–0.70	<0.001
Positive nodes (vs. 0)
1–3	2.31	2.00–2.67	<0.001		2.04	1.42–2.94	<0.001
4–9	4.07	3.43–4.83	<0.001		3.67	2.30–5.86	<0.001
≥10	4.98	4.12–6.02	<0.001		4.33	2.70–6.93	<0.001
Radiation recodes (vs. yes)
No/unknown	1.17	1.07–1.28	0.001		1.11	0.86–1.45	0.424
Chemotherapy recodes (vs. yes)
No/unknown	0.98	0.89–1.09	0.732		1.65	1.23–2.23	<0.001
Metastasis site (vs. M0)
Only bone	3.61	3.12–4.18	<0.001		4.99	2.61–9.51	<0.001
Only visceral	4.33	3.54–5.29	<0.001		3.58	2.24–5.72	<0.001
Only bone + only visceral	5.58	4.69–6.64	<0.001		6.83	3.90–11.96	<0.001
Multiple visceral metastasis	7.95	6.38–9.90	<0.001		46.12	25.10–84.72	<0.001

ER, estrogen receptor; PR, progesterone receptor; IDC, intraductal carcinoma; CSS, cancer specific survival; TNBC, triple-negative breast cancer.